The product is bioequivalent to Eli Lilly and company's Glucagon for Injection, 1 mg/vial, and is used in the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes mellitus. It is also indicated as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal motility in adult patients.
According to IQVIA MAT (June 2025) data, Glucagon for Injection USP, 1 mg/vial packaged in an emergency kit, had estimated annual sales of $122 million in the U.S. market.
Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Lupin’s consolidated net profit jumped 52.13% to Rs 1,219.03 crore on 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."